MXPA05008342A - Listeria atenuada para la entrada a las celulas no fagociticas, vacunas que comprenden la listeria, y metodos de uso de las mismas. - Google Patents

Listeria atenuada para la entrada a las celulas no fagociticas, vacunas que comprenden la listeria, y metodos de uso de las mismas.

Info

Publication number
MXPA05008342A
MXPA05008342A MXPA05008342A MXPA05008342A MXPA05008342A MX PA05008342 A MXPA05008342 A MX PA05008342A MX PA05008342 A MXPA05008342 A MX PA05008342A MX PA05008342 A MXPA05008342 A MX PA05008342A MX PA05008342 A MXPA05008342 A MX PA05008342A
Authority
MX
Mexico
Prior art keywords
listeria
attenuated
methods
vaccines
entry
Prior art date
Application number
MXPA05008342A
Other languages
English (en)
Inventor
David Cook
Original Assignee
Cerus Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cerus Corp filed Critical Cerus Corp
Publication of MXPA05008342A publication Critical patent/MXPA05008342A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/07—Bacillus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/04—Mycobacterium, e.g. Mycobacterium tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5154—Antigen presenting cells [APCs], e.g. dendritic cells or macrophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/522—Bacterial cells; Fungal cells; Protozoal cells avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/523—Bacterial cells; Fungal cells; Protozoal cells expressing foreign proteins

Abstract

La presente invencion proporciona Listeria que son atenuadas para la entrada a las celulas no fagociticas asi como una variedad de metodos para inducir respuestas inmunes que involucran la administracion de composiciones que incluyen la Listeria atenuada. Algunas de las Listerias atenuadas son Listeria mutantes que comprenden al menos una mutacion en un gen que codifica para una invasina, tal como internalina. Algunas de las Listerias atenuadas son ademas atenuadas para la dispersion de celula a celula. Se proporcionan tambien las composiciones farmaceuticas y las vacunas utiles en los metodos de la invencion. Se proporcionan tambien los metodos para elaborar y mejorar las vacunas.
MXPA05008342A 2003-02-06 2004-02-06 Listeria atenuada para la entrada a las celulas no fagociticas, vacunas que comprenden la listeria, y metodos de uso de las mismas. MXPA05008342A (es)

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US44605103P 2003-02-06 2003-02-06
US44915303P 2003-02-21 2003-02-21
US49008903P 2003-07-24 2003-07-24
US51171903P 2003-10-15 2003-10-15
US51191903P 2003-10-15 2003-10-15
US51186903P 2003-10-15 2003-10-15
US54151504P 2004-02-02 2004-02-02
PCT/US2004/003429 WO2004110481A2 (en) 2003-02-06 2004-02-06 Listeria attenuated for entry into non-phagocytic cells, vaccines comprising the listeria, and methods of use thereof

Publications (1)

Publication Number Publication Date
MXPA05008342A true MXPA05008342A (es) 2006-02-28

Family

ID=33556840

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA05008342A MXPA05008342A (es) 2003-02-06 2004-02-06 Listeria atenuada para la entrada a las celulas no fagociticas, vacunas que comprenden la listeria, y metodos de uso de las mismas.

Country Status (13)

Country Link
US (2) US7691393B2 (es)
EP (1) EP1592441B1 (es)
JP (2) JP4545151B2 (es)
KR (1) KR101192652B1 (es)
AT (1) ATE552843T1 (es)
AU (1) AU2004246999B2 (es)
CA (1) CA2515369C (es)
DK (1) DK1592441T3 (es)
ES (1) ES2382332T3 (es)
HK (1) HK1082187A1 (es)
MX (1) MXPA05008342A (es)
PT (1) PT1592441E (es)
WO (1) WO2004110481A2 (es)

Families Citing this family (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7794729B2 (en) * 1994-11-08 2010-09-14 The Trustees Of The University Of Pennsylvania Methods and compositions for immunotherapy of cancer
US7635479B2 (en) * 2000-03-29 2009-12-22 The Trustees Of The University Of Pennsylvania Composition and methods for enhancing immunogenecity of antigens
US7662396B2 (en) * 2001-03-26 2010-02-16 The Trustees Of The University Of Pennsylvania Compositions and methods for enhancing the immunogenicity of antigens
US20070264279A1 (en) * 1994-11-08 2007-11-15 Claudia Gravekamp Compositions and methods comprising a MAGE-b antigen
US8791237B2 (en) 1994-11-08 2014-07-29 The Trustees Of The University Of Pennsylvania Compositions and methods for treatment of non-hodgkins lymphoma
US8114414B2 (en) * 1994-11-08 2012-02-14 The Trustees Of The University Of Pennsylvania Compositions and methods for treatment of cervical cancer
US8956621B2 (en) 1994-11-08 2015-02-17 The Trustees Of The University Of Pennsylvania Compositions and methods for treatment of cervical dysplasia
US7820180B2 (en) * 2004-09-24 2010-10-26 The Trustees Of The University Of Pennsylvania Listeria-based and LLO-based vaccines
US6099848A (en) * 1997-11-18 2000-08-08 The Trustees Of The University Of Pennsylvania Immunogenic compositions comprising DAL/DAT double-mutant, auxotrophic, attenuated strains of Listeria and their methods of use
US9012141B2 (en) 2000-03-27 2015-04-21 Advaxis, Inc. Compositions and methods comprising KLK3 of FOLH1 antigen
US7700344B2 (en) 2001-03-26 2010-04-20 The Trustees Of The University Of Pennsylvania Compositions and methods for enhancing the immunogenicity of antigens
US8771702B2 (en) 2001-03-26 2014-07-08 The Trustees Of The University Of Pennsylvania Non-hemolytic LLO fusion proteins and methods of utilizing same
EP1513924A4 (en) * 2002-05-29 2008-05-21 Univ California ATTENUATED LISTERIA SPP. AND METHOD OF USE THEREOF
US7695725B2 (en) * 2003-02-06 2010-04-13 Aduro Biotech Modified free-living microbes, vaccine compositions and methods of use thereof
WO2004084936A2 (en) * 2003-02-06 2004-10-07 Cerus Corporation Modified free-living microbes, vaccine compositions and methods of use thereof
ES2382332T3 (es) * 2003-02-06 2012-06-07 Aduro Biotech Listeria atenuada para entrar en células no fagocíticas, vacunas que comprenden esta listeria y métodos de uso de las mismas
US20050175630A1 (en) * 2003-12-23 2005-08-11 Eyal Raz Immunogenic compositions and methods of use thereof
US7842289B2 (en) 2003-12-24 2010-11-30 Aduro Biotech Recombinant nucleic acid molecules, expression cassettes, and bacteria, and methods of use thereof
US20060003454A1 (en) * 2004-07-02 2006-01-05 Conjugon, Inc. Non-dividing donor cells for gene transfer
CA2584130A1 (en) * 2004-10-18 2006-04-27 Medimmune, Inc. High cell density process for growth of listeria
US20060270040A1 (en) * 2005-05-26 2006-11-30 Conjugon, Inc. Compositions and methods for treating tissue
US7935804B2 (en) 2006-03-01 2011-05-03 Aduro Biotech Engineered Listeria and methods of use thereof
PT1991263E (pt) * 2006-03-01 2015-03-03 Aduro Biotech Listeria geneticamente modificada e métodos de uso da mesma
US20070207171A1 (en) * 2006-03-01 2007-09-06 Cerus Corporation Engineered listeria and methods of use thereof
WO2008094188A2 (en) 2006-07-17 2008-08-07 Anza Therapeutics, Inc. Methods and compositions using listeria for enhancing immunogenicity by prime boost
WO2008019131A2 (en) * 2006-08-04 2008-02-14 The Trustees Of The University Of Pennsylvania Methods and compositions for treating ige-mediated diseases
US8268326B2 (en) * 2006-08-15 2012-09-18 The Trustees Of The University Of Pennsylvania Compositions comprising HMW-MAA and fragments thereof, and methods of use thereof
EP2977456B1 (en) * 2006-08-15 2017-10-25 The Trustees Of The University Of Pennsylvania Compositions comprising hmw-maa and fragments thereof for treating cancer
US8277797B2 (en) 2006-11-22 2012-10-02 The Regents Of The University Of California Interferon-β production modulating Listeria strains and methods for using same
AU2008265911B2 (en) * 2007-06-15 2013-05-16 Immurx, Inc. Use of TLR agonists and/or type 1 interferons to alleviate toxicity of TNF-R agonist therapeutic regimens
US8709445B2 (en) * 2007-07-31 2014-04-29 Los Angeles Biomedical Research Institute At Harbor-Ucla Medical Center Vaccination with killed but metabolically active (KBMA) protozoans with toll-like receptor agonists
US9017660B2 (en) 2009-11-11 2015-04-28 Advaxis, Inc. Compositions and methods for prevention of escape mutation in the treatment of Her2/neu over-expressing tumors
US9650639B2 (en) 2008-05-19 2017-05-16 Advaxis, Inc. Dual delivery system for heterologous antigens
CN102076843A (zh) 2008-05-19 2011-05-25 艾杜罗生物科技公司 包含prfa*突变体李斯特菌的组合物及其使用方法
EP2288379A4 (en) 2008-05-19 2012-08-08 Advaxis DOUBLE RELEASE SYSTEM FOR HETEROLOGIST ANTIGENE
US8778329B2 (en) 2009-03-04 2014-07-15 The Trustees Of The University Of Pennsylvania Compositions comprising angiogenic factors and methods of use thereof
US10016617B2 (en) 2009-11-11 2018-07-10 The Trustees Of The University Of Pennsylvania Combination immuno therapy and radiotherapy for the treatment of Her-2-positive cancers
EP2576791B8 (en) 2010-05-23 2016-12-21 Aduro BioTech, Inc. Methods and compositions using listeria for adjuvant treatment of cancer
EP2621527A4 (en) 2010-10-01 2015-12-09 Univ Pennsylvania USE OF LISTERIA VACCINE VECTORS TO REVERSE VACCINE IMMUNITY IN PATIENTS WITH PARASITIC INFECTIONS
CA2818353A1 (en) 2010-11-17 2012-05-24 Aduro Biotech Methods and compositions for inducing an immune response to egfrviii
AU2012229218B2 (en) * 2011-03-11 2017-03-02 Advaxis, Inc. Listeria-based adjuvants
DK3042704T3 (da) 2011-05-23 2019-06-11 Lego As Legetøjskonstruktionssystem
BR112014022662A2 (pt) 2012-03-12 2017-10-03 Advaxis Inc Inibição da função de célula supressora seguindo tratamento de vacina de listeria
MX2017004897A (es) 2014-10-14 2018-02-09 Univ Pennsylvania Cepas vacunales recombinantes de listeria y metodos para usar las mismas en la inmunoterapia contra el cancer.
WO2016073381A1 (en) 2014-11-03 2016-05-12 Cerus Corporation Compositions and methods for improved car-t cell therapies
UY36617A (es) 2015-04-13 2016-10-31 Aduro Biotech Inc Proteínas de fusión inmunogénicas para el tratamiento del cáncer
CR20170507A (es) 2015-04-13 2018-02-13 Aduro Biotech Inc Fusiones de variante iii del receptor de factor de crecimiento epidérmico-mesotelina y métodos para usar los mismos.
EP3313418B1 (en) 2015-06-26 2024-03-13 Cerus Corporation Cryoprecipitate compositions and methods of preparation thereof
EP3364986B1 (en) 2015-10-23 2023-12-13 Cerus Corporation Pathogen-inactivated cryo-poor plasma and methods of use thereof
BR112018012374A2 (pt) 2015-12-16 2018-12-04 Gritstone Oncology, Inc. identificação, fabricação e uso de neoantígeno
CN110573169A (zh) 2017-03-03 2019-12-13 塞鲁斯公司 制备病原体灭活的血小板组合物的试剂盒和方法
CA3075849A1 (en) 2017-09-19 2019-03-28 Advaxis, Inc. Compositions and methods for lyophilization of bacteria or listeria strains
CA3078744A1 (en) 2017-10-10 2019-04-18 Gritstone Oncology, Inc. Neoantigen identification using hotspots
AU2018373154A1 (en) 2017-11-22 2020-07-02 Gritstone Bio, Inc. Reducing junction epitope presentation for neoantigens
CN116571191A (zh) 2017-12-29 2023-08-11 塞鲁斯公司 用于处理生物流体的系统和方法
EP3762719A1 (en) 2018-03-09 2021-01-13 Advaxis, Inc. Compositions and methods for evaluating attenuation and infectivity of listeria strains
US20210239681A1 (en) 2018-04-27 2021-08-05 Advaxis, Inc. Compositions and methods for evaluating potency of listeria-based immunotherapeutics
WO2020024982A1 (zh) * 2018-08-02 2020-02-06 苏州若泰医药科技有限公司 一种基于减毒李斯特菌激活的抗原提呈细胞的肿瘤免疫治疗组合物、制备方法和应用
WO2020264421A1 (en) 2019-06-28 2020-12-30 Cerus Corporation System and methods for implementing a biological fluid treatment device
US10973908B1 (en) 2020-05-14 2021-04-13 David Gordon Bermudes Expression of SARS-CoV-2 spike protein receptor binding domain in attenuated salmonella as a vaccine
CN113845589B (zh) * 2021-08-20 2023-04-07 扬州大学 SmcL单克隆抗体、分泌该抗体的杂交瘤细胞株及其应用和竞争ELISA检测方法
CN114250244A (zh) * 2021-12-14 2022-03-29 浙江农林大学 以重组减毒单増李斯特菌为载体的结肠癌疫苗及制备方法

Family Cites Families (82)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5106619A (en) 1983-12-20 1992-04-21 Diamond Scientific Co. Preparation of inactivated viral vaccines
US4545987A (en) 1983-12-20 1985-10-08 Advanced Genetics Research Institute Psoralen inactivated double-stranded RNA viral vaccines
US4556556A (en) 1984-03-23 1985-12-03 Advanced Genetics Research Institute Vaccine for the prevention of vesicular stomatitis virus infection
US5171568A (en) 1984-04-06 1992-12-15 Chiron Corporation Recombinant herpes simplex gb-gd vaccine
US4791062A (en) 1985-02-28 1988-12-13 Diamond Scientific Co. FVR vaccine
CN1074422C (zh) 1987-11-18 2001-11-07 希龙股份有限公司 制备含有hcv表位的分离多肽的方法
DK189788D0 (da) 1988-04-07 1988-04-07 Wolf Watz Hans Vaccine
HU225068B1 (en) 1989-03-17 2006-05-29 Chiron Corp Process for producing diagnostics and vaccine of nanbh
MC2188A1 (fr) 1989-05-18 1992-09-16 Chiron Corp Diagnostic du nanbv:polynucleotides permettant de depister le virus de l'hepatite c
US5180819A (en) 1989-12-22 1993-01-19 The Trustees Of Columbia University In The City Of New York Purified myeloblastin, nucleic acid molecule encoding same, and uses thereof
US5830702A (en) 1990-10-31 1998-11-03 The Trustees Of The University Of Pennsylvania Live, recombinant listeria monocytogenes and production of cytotoxic T-cell response
FR2686896B1 (fr) * 1992-01-31 1995-01-06 Pasteur Institut Mutant attenue de listeria monocytogenes; souche recombinante de listeria monocytogenes, utilisation comme vecteurs heterologues d'antigenes vaccinal et utilisation comme vaccin ou composition diagnostique.
US5593823A (en) 1993-06-28 1997-01-14 Cerus Corporation Method for inactivating pathogens in blood using photoactivation of 4'-primary amino-substituted psoralens
US5399719A (en) 1993-06-28 1995-03-21 Steritech, Inc. Compounds for the photodecontamination of pathogens in blood
US6051237A (en) 1994-11-08 2000-04-18 The Trustees Of The University Of Pennsylvania Specific immunotherapy of cancer using a live recombinant bacterial vaccine vector
US7635479B2 (en) 2000-03-29 2009-12-22 The Trustees Of The University Of Pennsylvania Composition and methods for enhancing immunogenecity of antigens
US5691132A (en) 1994-11-14 1997-11-25 Cerus Corporation Method for inactivating pathogens in red cell compositions using quinacrine mustard
US5877159A (en) 1995-05-03 1999-03-02 University Of Maryland At Baltimore Method for introducing and expressing genes in animal cells and live invasive bacterial vectors for use in the same
US6682729B1 (en) 1995-05-03 2004-01-27 University Of Maryland, Baltimore Method for introducing and expressing genes in animal cells, and live invasive bacterial vectors for use in the same
US6150170A (en) 1998-05-03 2000-11-21 University Of Maryland At Baltimore Method for introducing and expressing genes in animal cells, and live invasive bacterial vectors for use in the same
US6177441B1 (en) 1995-06-05 2001-01-23 Cerus Corporation Treating red blood cell solutions with anti-viral agents
AU722811B2 (en) 1995-06-07 2000-08-10 Cerus Corporation Treating red blood cell solutions with anti-viral agents
GB9521568D0 (en) 1995-10-20 1995-12-20 Lynxvale Ltd Delivery of biologically active polypeptides
AU1152397A (en) 1995-12-20 1997-07-14 Board Of Trustees Of The Leland Stanford Junior University Methods for in vivo t cell activation by antigen-pulsed dendritic cells
ATE254931T1 (de) 1996-01-05 2003-12-15 Us Gov Health & Human Serv Mesothelinantigen, verfahren und testsatz zur targetierung
US5843459A (en) 1996-01-19 1998-12-01 Human Gene Therapy Research Institute Differential inactivation of nucleic acids by chemical modification
AU2331597A (en) * 1996-03-22 1997-10-10 Yale University Methods for inducing immune responsiveness in a subject
JP2000516911A (ja) 1996-03-28 2000-12-19 ホワイトヘッド インスティテュート フォー バイオメディカル リサーチ オプソニン強化細胞、および抗原に対する免疫応答を調節する方法
EP0808897A1 (en) 1996-05-21 1997-11-26 I.D.M. Immuno-Designed Molecules New antigen presenting cells, a process for preparing the same and their use as cellular vaccines
WO1998001538A1 (en) 1996-07-10 1998-01-15 Immunex Corporation Method of activating dendritic cells
GB9615022D0 (en) 1996-07-17 1996-09-04 Mini Agriculture & Fisheries Vaccine preparations
US7273753B2 (en) 1996-08-02 2007-09-25 Center Of Blood Research Purification and uses of dendritic cells and monocytes
WO1998005795A1 (en) 1996-08-02 1998-02-12 The Center For Blood Research, Inc. Enrichment of dendritic cells from blood
DE19635676A1 (de) 1996-09-03 1998-03-05 Basf Ag Feste geschäumte Wirkstoffzubereitungen
TW555562B (en) * 1996-12-27 2003-10-01 Kirin Brewery Method for activation of human antigen-presenting cells, activated human antigen-presenting cells and use thereof
US6514987B1 (en) 1997-01-06 2003-02-04 Cerus Corporation Frangible compounds for pathogen inactivation
CN101676268B (zh) 1997-01-06 2013-09-25 塞鲁斯公司 用于病原体灭活的脆性化合物
US6093725A (en) 1997-01-06 2000-07-25 Cerus Corporation Frangible compounds for pathogen inactivation
GB9700939D0 (en) 1997-01-17 1997-03-05 Microbial Technics Limited Therapy
AU6050398A (en) 1997-01-31 1998-08-25 Vanderbilt University Method of delivering antigens for vaccination with a live vector
CA2296366A1 (en) 1997-07-21 1999-01-28 Cerus Corporation Method of treating leukocytes, leukocyte compositions and methods of use thereof
EP0902086A1 (en) * 1997-08-22 1999-03-17 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Tuberculosis vaccine
US6099848A (en) 1997-11-18 2000-08-08 The Trustees Of The University Of Pennsylvania Immunogenic compositions comprising DAL/DAT double-mutant, auxotrophic, attenuated strains of Listeria and their methods of use
JP2003525848A (ja) 1997-11-20 2003-09-02 セラス コーポレーション 病原体を不活化するための新規なソラレン
DE19754938B4 (de) * 1997-12-11 2006-04-20 Christoph von Dr. Eichel-Streiber TGC-Verfahren zur Induktion einer zielgerichteten, somatischen Transgenität
US6143551A (en) 1997-12-29 2000-11-07 Schering Aktiengesellschaft Delivery of polypeptide-encoding plasmid DNA into the cytosol of macrophages by attenuated listeria suicide bacteria
DE69826521T2 (de) 1998-01-06 2005-09-29 Cerus Corp., Concord Verfahren zum quenchen von pathogen-inaktivatoren in biologischen materialien
AU756911B2 (en) 1998-03-20 2003-01-23 Biopolo S.C.R.L. Processes for improved presentation of antigens by dendritic cells
EP1068296B1 (en) 1998-03-31 2011-08-10 Geron Corporation Compositions for eliciting an immune response to a telomerase antigen
US20020155108A1 (en) 1998-05-04 2002-10-24 Biocrystal, Ltd. Method for ex vivo loading of antigen presenting cells with antigen, and a vaccine comprising the loaded cells
US6254863B1 (en) 1998-08-12 2001-07-03 Loma Linda University Non-virulent Porphyromonas gingivalis mutant
US6004815A (en) 1998-08-13 1999-12-21 The Regents Of The University Of California Bacteria expressing nonsecreted cytolysin as intracellular microbial delivery vehicles to eukaryotic cells
GB9918283D0 (en) 1999-08-03 1999-10-06 Int Centre Genetic Eng & Bio Hsv vaccines
AU7856100A (en) 1999-10-04 2001-05-10 Vion Pharmaceuticals, Inc. Methods for treating solid tumors with irradiation and bacteria
DE19949594A1 (de) * 1999-10-14 2001-04-26 Deutsches Krebsforsch Rekombinante attenuierte Listerien zur Immuntherapie
US20030077263A1 (en) 1999-10-29 2003-04-24 Immunex Corporation Method of activating dendritic cells
GB0007150D0 (en) * 2000-03-24 2000-05-17 Lamellar Therapeutics Limited Immunotherapeutic methods and compositions
US6855320B2 (en) 2000-03-29 2005-02-15 The Trustees Of The University Of Pennsylvania Fusion of non-hemolytic, truncated form of listeriolysin O to antigens to enhance immunogenicity
JP2003531841A (ja) 2000-05-04 2003-10-28 プレジデント・アンド・フェロウズ・オブ・ハーバード・カレッジ 微生物感染の治療と予防のための化合物と方法
WO2002024739A2 (en) 2000-09-21 2002-03-28 The Regents Of The University Of California Spas-1 cancer antigen
WO2002040646A1 (en) 2000-11-14 2002-05-23 Universite Libre De Bruxelles Generation and use of dendritic cells
AU2001298078A1 (en) 2000-12-21 2003-09-02 Cerus Corporation Methods for inactivation of pathogens in biological materials
US6783765B2 (en) 2001-03-23 2004-08-31 Council Of Scientific And Industrial Research Process for the preparation of a vaccine for the treatment of tuberculosis and other intracellular infections diseases and the vaccine produced by the process
AU2002249531A1 (en) 2001-04-02 2002-10-28 Alimentary Health Limited Immunotherapy based on dendritic cells
US7566568B2 (en) 2001-04-27 2009-07-28 Istituto Superiore Di Sanita Method for generating highly active human dendritic cells from peripheral blood mononuclear cells
US20040022761A1 (en) 2001-05-11 2004-02-05 Banchereau Jacques F Compositions and methods for producing antigen-presenting cells
WO2003012085A1 (en) 2001-07-30 2003-02-13 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Antigen presenting cells, method for their preparation and their use for cancer vaccines
US7413869B2 (en) 2002-04-05 2008-08-19 Dendreon Corporation Method for determining potency of antigenic presenting cell based vaccines
US7425449B2 (en) 2002-04-30 2008-09-16 The Regents Of The University Of California Site specific Listeria integration vectors and methods for using the same
EP1513924A4 (en) 2002-05-29 2008-05-21 Univ California ATTENUATED LISTERIA SPP. AND METHOD OF USE THEREOF
US20040009194A1 (en) 2002-06-21 2004-01-15 Jean-Marie Andrieu Methods, and compositions for a therapeutic antigen presenting cell vaccine for treatment of immunodeficiency virus
AU2002950473A0 (en) 2002-07-26 2002-09-12 Commonwealth Scientific And Industrial Research Organisation Expression system
ES2382332T3 (es) * 2003-02-06 2012-06-07 Aduro Biotech Listeria atenuada para entrar en células no fagocíticas, vacunas que comprenden esta listeria y métodos de uso de las mismas
WO2004084936A2 (en) 2003-02-06 2004-10-07 Cerus Corporation Modified free-living microbes, vaccine compositions and methods of use thereof
US7695725B2 (en) 2003-02-06 2010-04-13 Aduro Biotech Modified free-living microbes, vaccine compositions and methods of use thereof
KR20060130038A (ko) 2003-10-15 2006-12-18 메디뮨 인코포레이티드 리스테리아에 의거한 ＥｐｈＡ２ 백신
US20050175630A1 (en) 2003-12-23 2005-08-11 Eyal Raz Immunogenic compositions and methods of use thereof
WO2005067460A2 (en) 2003-12-24 2005-07-28 Medimmune, Inc. Epha2 vaccines
CA2551644C (en) 2003-12-24 2014-03-04 Cerus Corporation Recombinant nucleic acid molecules encoding fusion proteins comprising antigens and bacterial secretory signal polypeptides, expression cassettes, and bacteria, and methods of usethereof
US7842289B2 (en) 2003-12-24 2010-11-30 Aduro Biotech Recombinant nucleic acid molecules, expression cassettes, and bacteria, and methods of use thereof
US20070031457A1 (en) 2004-02-06 2007-02-08 Dubensky Thomas W Jr Modified Bacillus anthracis, vaccine compositions and methods of use thereof
WO2005092372A2 (en) 2004-02-06 2005-10-06 Cerus Corporation Modified bacillus anthracis vaccine compositions and methods of use thereof

Also Published As

Publication number Publication date
AU2004246999A1 (en) 2004-12-23
PT1592441E (pt) 2012-05-21
US7691393B2 (en) 2010-04-06
KR20050105460A (ko) 2005-11-04
WO2004110481A3 (en) 2005-03-03
US20040228877A1 (en) 2004-11-18
JP2007125040A (ja) 2007-05-24
ATE552843T1 (de) 2012-04-15
ES2382332T3 (es) 2012-06-07
US8287883B2 (en) 2012-10-16
EP1592441B1 (en) 2012-04-11
CA2515369A1 (en) 2004-12-23
AU2004246999B2 (en) 2010-06-10
HK1082187A1 (en) 2006-06-02
KR101192652B1 (ko) 2012-10-19
WO2004110481A2 (en) 2004-12-23
CA2515369C (en) 2015-03-31
JP4545151B2 (ja) 2010-09-15
JP2007503846A (ja) 2007-03-01
US20110201092A1 (en) 2011-08-18
EP1592441A2 (en) 2005-11-09
DK1592441T3 (da) 2012-05-14

Similar Documents

Publication Publication Date Title
HK1082187A1 (en) Listeria attenuated for entry into non-phagocytic cells, vaccines comprising the listeria, and methods of use thereof
MXPA05013973A (es) Metodos para producir, mejorar y sustentar respuestas inmunes contra epitopes restringidos mhc clase i, para propositos profilacticos o terapeuticos.
NO20031646L (no) Adjuvanssammensetning omfattende et immunostimulatorisk oligonukleotid og en tokol
HK1044484A1 (en) Adjuvant composition comprising saponin and an immunostimulatory oligonucleotide.
WO2005037233A3 (en) Listeria-based epha2 vaccines
MX2009003325A (es) Vacuna que comprende un adyuvante de emulsion de aceite en agua.
HUP0101619A2 (hu) Adjuvánskészítmények
IN2014DN08830A (es)
IL136131A0 (en) Recombinant vaccines comprising immunogenic attenuated bacteria having rpos positive phenotype
HK1100480A1 (en) Generally linear effervescent oral fentanyl dosage form and methods of administering
WO2003040168A3 (en) Methods and compositions for identifying peptide aptamers capable of altering a cell phenotype
EP1326633A4 (en) COMPOSITION WITH IMMUNOGENIC MICROPARTICLES
MXPA04001509A (es) Particulas de fosfato de calcio como coadyuvantes para la mucosa.
DE60136563D1 (de) Salmonella vakzine
PL343246A1 (en) Bacteria attenuated by a non-reverting mutation in each of the aroc, ompf and ompc genes, useful as vaccines
AR030882A1 (es) Microbios que tienen una mutacion atenuante que comprenden un terminador de transcripcion
HK1071079A1 (en) Use of soluble fgl2 as an immunosuppressant
WO2003106640A3 (en) CELL TARGETING METHODS AND COMPOSITIONS
WO2003093298A3 (en) Immunogenic peptides
Kaya et al. The effects on immune response of levamisole treatment following infection of U-937 macrophages with Candida albicans
MY127452A (en) Vaccines.
ATE353226T1 (de) Adjuvanszusammensetzung enthaltend fha oder ein fha-fragment in freier form
NZ514027A (en) Cloning and expression of haemophilus somnus transferrin-binding proteins
WO2002100317A3 (en) Targeted particles and methods of using the same
Chin Life in a melting pot

Legal Events

Date Code Title Description
GB Transfer or rights
FG Grant or registration
GB Transfer or rights